Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ITK | Q08881 | 2/20 | 0.32 |
| ▸ | UBE2N | P61088 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 2/20 | 0.31 |
| ▸ | TXK | P42681 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3403873 | 0.89 | MEN1 (0.34) | MEN1KMT2ANPC1UBE2NSMN1; SMN2 | |
| SCHEMBL3403831 | 0.89 | NPC1 (0.34) | MEN1KMT2ANPC1UBE2N | |
| SCHEMBL3405883 | 0.86 | CYP1A2 (0.36) | MEN1KMT2ANPC1UBE2NMLYCD | |
| SCHEMBL3405727 | 0.86 | MMP2 (0.35) | MAPTMMP2 | |
| SCHEMBL3405793 | 0.86 | POLB (0.36) | MEN1KMT2AMAPTRAB9A | |
| SCHEMBL3404511 | 0.85 | S1PR1 (0.39) | MEN1KMT2AMLYCD | |
| SCHEMBL3405142 | 0.84 | MLYCD (0.43) | MEN1KMT2ANPC1TP53L3MBTL1 | |
| SCHEMBL3404000 | 0.84 | CA2 (0.39) | MEN1KMT2ANPC1UBE2NRAB9A | |
| SCHEMBL3407428 | 0.82 | MLYCD (0.34) | MEN1KMT2ANPC1TP53L3MBTL1 | |
| SCHEMBL3407594 | 0.81 | TP53 (0.37) | MEN1KMT2ANPC1TP53L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370260-B1 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-11-24 | — | — | EP | claimed |
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-13 | — | — | US | claimed |
| EP-1370260-A2 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-12-17 | — | — | EP | claimed |
| WO-2002066035-A2 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | ME1, ME3, ME2 | MEN1 669/4885KMT2A 1536/4885NPC1 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.